5-Year Analysis of the Phase III COMFORT-II Study Comparing Ruxolitinib to Best Available Therapy for the Treatment of Myelofibrosis


5-Year Analysis of the Phase III COMFORT-II Study Comparing Ruxolitinib to Best Available Therapy for the Treatment of Myelofibrosis
Slides from a presentation at ASH 2015

Harrison CN et al. Long-term efficacy and safety in COMFORT-II, a Phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis: 5-year final study results. Proc ASH 2015;Abstract 59.